Cardiol Therapeutics Inc. Stock Analysis & AI Score
Cardiol Therapeutics Inc. (CRDL) has an ST Score of 60.5 (B), driven by its Financial Strength (A+) and held back by its Profitability (C-). Analysts rate it Buy with a $8.00 price target (+362.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Cardiol Therapeutics Inc. (CRDL) has an ST Score of 60.5 (B), driven by its Financial Strength (A+) and held back by its Profitability (C-). Analysts rate it Buy with a $8.00 price target (+362.4% upside).
- Strongest
- Financial StrengthA+
- Weakest
- ProfitabilityC-
All factor grades
- Financial StrengthA+
- ForecastA
- ValuationA-
- MomentumB+
- GrowthC
- ProfitabilityC-
- Piotroski2/9
Contact
CRDL stock: frequently asked questions
What is CRDL's ST Score?
Cardiol Therapeutics Inc. (CRDL) has an ST Score of 60.5 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CRDL a buy, hold, or sell?
Analysts rate CRDL a Buy, with a price target of $8.00 (+362.4% vs the current price). Our ST Score grades it B (60.5/100). The ST Score is a data-driven signal, not a recommendation.
What are CRDL's factor grades?
Valuation A-, Profitability C-, Financial Strength A+, Momentum B+, Growth C, Forecast A.
What is CRDL's valuation grade?
Cardiol Therapeutics Inc. (CRDL) earns a valuation grade of A-, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CRDL's growth grade?
Cardiol Therapeutics Inc. (CRDL) earns a growth grade of C, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CRDL's profitability grade?
Cardiol Therapeutics Inc. (CRDL) earns a profitability grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CRDL's financial strength grade?
Cardiol Therapeutics Inc. (CRDL) earns a financial strength grade of A+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CRDL?
The average analyst price target for Cardiol Therapeutics Inc. (CRDL) is $8.00 from 2 analysts, which is +362.4% versus the recent price of $1.73.
What is CRDL's Piotroski score?
Cardiol Therapeutics Inc. (CRDL) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.